- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03624244
Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS) (BFR-ESS)
Randomized Comparative Prospective Multicentre Phase II Trial Evaluating Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic LGESS
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Uterine sarcomas are rare tumors with an incidence of 1.7/100 000 women per year, including 20% of endometrial stromal sarcomas (ESS). Patients with low grade ESS (LGESS) have a good prognosis with a 5-year overall survival rates ranging from 66 to 98%, depending on the stage of the disease.
Majority of LGESS report estrogen receptor (ER) and/or progesterone receptor positive and a chromosomal translocation with JAZF1-SUZ12.
Based on the current European Society of Medical Oncology (ESMO)guidelines, the standard treatment for patients with early/non metastatic ESS is total hysterectomy plus or less bilateral salpingo-oophorectomy. The use of hormonal therapy (HT) for advanced or metastatic disease is recommended based on retrospective data from small series providing evidence that HT have an anti-tumor activity on LGESS. HT includes aromatase inhibitors (AI), progestins and gonadotrophin-releasing hormone.
Very few data are available in this rare disease, but retrospective analyses show that AI may provide response rates of 46 to 67% in metastatic LGESS patients (7% complete response, 60% partial response), with a mean duration of response of 24 months.
Even if AI are effective and well tolerated, chronical mild to moderate (grade 1-2) side-effects (arthritis, hot-flashes, osteoporosis, hypercholesterolemia, cardiac events) have a negative impact on patient's well-being because of the treatment long term duration and need to be balanced in such long term survival.
To date, the question of the optimal duration of HT in LGESS is still pending. The investigator propose an open-label, randomized, multicenter phase II study aiming at determining the feasibility of interruption of AI in patients with locally advanced or metastatic LGESS after long term stabilization or response to AI. The study will use a sequential bayesian design allowing for continuous monitoring of the main efficacy outcome, thus leading to a smaller more informative trial, and specifically tied to decision making. This design is particularly suited to characterize efficacy signals in the context of a very rare pathology. Moreover JAZF1-JJAZ1 fusion gene is not identified in all LGESS.
Ancillary studies will provide precious data aiming at:
- Identifying predictive factors of prolonged response to HT or late resistance (Next Generation Sequencing and Comparative Genome Hybridization).
- Evaluating sociobehavioral (only for French sites) of patients by following questionnaire: Zimbardo Time Perspective Inventory (ZTPI) , Functional, Communicative and Critical Health Literacy/ 14-item Health Literacy Scale (FCCHL/HLS14), VICAN, Fear of Cancer Recurrence (FCR) and Patient-Generated Index (PGI).
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Séverine METZGER
- Phone Number: +33478782786
- Email: severine.metzger@lyon.unicancer.fr
Study Contact Backup
- Name: Isabelle RAY-COQUARD, MD PhD
- Phone Number: +33478782828
- Email: isabelle.ray-coquard@lyon.unicancer.fr
Study Locations
-
-
-
Besançon, France, 25030
- Recruiting
- CHU Besançon
-
Contact:
- Loic CHAIGNEAU, MD
- Phone Number: +33381668705
- Email: lchaigneau@chu-besancon.fr
-
Bordeaux, France
- Recruiting
- Insitut Bergonié
-
Contact:
- FLOQUET Anne
- Email: A.Floquet@bordeaux.unicancer.fr
-
Caen, France, 14076
- Recruiting
- Centre Francois Baclesse
-
Contact:
- Sabine NOAL, MD
- Phone Number: +33231455017
- Email: s.noal@baclesse.unicancer.fr
-
Clermont-Ferrand, France, 63000
- Recruiting
- Centre Jean Perrin
-
Contact:
- Pascale DUBRAY-LONGERAS
- Phone Number: +33473278141
- Email: pascale.dubray-longeras@cjp.fr
-
Lille, France, 59000
- Recruiting
- Centre Oscar Lambret
-
Contact:
- Nicolas PENEL, MD
- Email: n-penel@o-lambret.fr
-
Limoges, France
- Recruiting
- Chu Dupuytren
-
Contact:
- VENAT-BOUVET Laurence
- Email: laurence.venat-bouvet@chu-limoges.fr
-
Lyon, France, 69373
- Recruiting
- Centre Leon Berard
-
Contact:
- Isabelle RAY-COQUARD, MD PhD
- Phone Number: +33478782828
- Email: isabelle.ray-coquard@lyon.unicancer.fr
-
Marseille, France
- Recruiting
- Institut Paoli Calmette
-
Contact:
- BERTUCCI François
- Email: BERTUCCIF@ipc.unicancer.fr
-
Marseille, France, 13005
- Recruiting
- Hôpital La Timone
-
Contact:
- Florence DUFFAUD, MD
- Email: florence.duffaud@ap-hm.fr
-
Montpellier, France, 34298
- Recruiting
- Institut de Cancérologie de Montpellier
-
Contact:
- Michel FABBRO
- Phone Number: +33467613063
- Email: michel.fabbro@icm.unicancer.fr
-
Nice, France, 06189
- Not yet recruiting
- Centre Antoine Lacassagne
-
Contact:
- Esma SAADA-BOUZID
- Phone Number: +33492031514
- Email: esma.saada-bouzid@nice.unicancer.fr
-
Paris, France, 75013
- Recruiting
- Hopital Pitie Salpetriere
-
Contact:
- Jean-Philippe SPANO
- Phone Number: +33142160509
- Email: jean-philippe.spano@aphp.fr
-
Paris, France
- Recruiting
- AP-HP Hôpital Cochin
-
Contact:
- ALEXANDRE Jérôme
- Email: jerome.alexandre@aphp.fr
-
Paris, France
- Recruiting
- Insitut Curie
-
Contact:
- WATSON Sarah, MD
- Email: sarah.watson@curie.fr
-
Reims, France
- Recruiting
- Institut Godinot
-
Contact:
- SAVOYE Aude-Marie
- Email: aude-marie.savoye@reims.unicancer.fr
-
Rouen, France
- Recruiting
- Centre Henri Becquerel
-
Contact:
- GUILLEMET Cécile
- Email: cecile.guillemet@chb.unicancer.fr
-
Saint-Herblain, France, 44805
- Recruiting
- ICO Centre Rene Gauducheau
-
Contact:
- Emmanuelle BOMPAS
- Email: emmanuelle.bompas@ico.unicancer.fr
-
Saint-Priest-en-Jarez, France
- Recruiting
- CHUSE
-
Contact:
- FOURNEL Pierre, MD
- Email: pierre.fournel@chu-st-etienne.fr
-
Saint-Étienne, France, 42020
- Recruiting
- Hôpital privé de la Loire
-
Contact:
- Olivier COLLARD, MD
- Email: olivier.collard@ramsaysante.fr
-
Tours, France, 37044
- Recruiting
- Chu Tours
-
Contact:
- Hélène VEGAS
- Email: h.vegas@chu-tours.fr
-
Villejuif, France, 94805
- Recruiting
- Institut Gustave Roussy
-
Contact:
- Patricia PAUTIER, MD
- Email: patricia.pautier@gustaveroussy.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age≥18 years;
- Histological confirmation of low grade ESS;
- Locally advanced or metastatic disease at diagnosis or patient experiencing a tumor effraction during hysterectomy;
- Treatment with aromatase inhibitors (Anastrozole or Exemestane or Letrozole ) initiated either: for at least 24 months (in patients with no residual disease or non-measurable disease at the last AI initiation) OR for at least 36 months (in patients with measurable disease at the last AI initiation);
- Disease must be controlled at the time of the randomisation (objective response or stable disease) by the aromatase inhibitor initiated either for at least 24 or 36 months
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 2
- Covered by a medical insurance;
- Signed informed consent prior to any study-specific procedure.
Exclusion Criteria:
- Pregnant or breastfeeding woman;
- Patient concurrently using other approved or investigational antineoplastic agents;
- Major concurrent disease affecting cardiovascular system, liver, kidneys, hematopoietic system or else considered as clinically important by the investigator and that could be incompatible with patient's participation in this trial or would likely interfere with study procedures or results;
- Prior history of malignancies other than study disease (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix) unless the patient has been free of the disease for at least 3 years;
- Patients using prohibited concomitant and/or concurrent medications
- Contra-indication according to SmPCs.
- Patient requiring tutorship or curatorship.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Interruption of aromatase inhibitors
Interruption of aromatase inhibitors until progression disease.
At disease progression, AI can be reintroduced.
|
Maintenance of AI versus interruption of AI
Other Names:
|
Other: Maintenance of aromatase inhibitors
|
Maintenance of AI versus interruption of AI
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival
Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
|
Progression free survival
|
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: From date of randomization to death due to any cause, assessed up to 60 months
|
Overall survival
|
From date of randomization to death due to any cause, assessed up to 60 months
|
Time to first subsequent chemotherapy/treatment or death
Time Frame: From date of randomization to the earliest date of chemotherapy/treatment start date following study treatment discontinuation, or death due to any cause, whichever came first, assessed up to 60 months
|
Time to first subsequent chemotherapy/treatment or death
|
From date of randomization to the earliest date of chemotherapy/treatment start date following study treatment discontinuation, or death due to any cause, whichever came first, assessed up to 60 months
|
Objective response rate after reintroduction of AI in the experimental arm
Time Frame: From the date of AI reintroduction in the experimental arm to the date of subsequent progression or date of death due to any cause, whichever came first, assessed up to 60 months
|
Proportion of patients with a best overall response of Partial Response (PR) or Complete Response (CR) after AI reintroduction in the experimental arm
|
From the date of AI reintroduction in the experimental arm to the date of subsequent progression or date of death due to any cause, whichever came first, assessed up to 60 months
|
Progression free survival after reintroduction of AI in the experimental arm
Time Frame: From the date of AI reintroduction in the experimental arm to the date of subsequent progression or date of death due to any cause, whichever came first, assessed up to 60 months
|
Progression free survival after reintroduction of AI in the experimental arm
|
From the date of AI reintroduction in the experimental arm to the date of subsequent progression or date of death due to any cause, whichever came first, assessed up to 60 months
|
Duration of response to AI after reintroduction
Time Frame: From the date of first objective response following the reintroduction of AI to the date of the first subsequent documented radiological progression or death due to any cause, whichever came first, assessed up to 60 months
|
Duration of response to AI after reintroduction
|
From the date of first objective response following the reintroduction of AI to the date of the first subsequent documented radiological progression or death due to any cause, whichever came first, assessed up to 60 months
|
Incidence of Treatment-Emergent Adverse Events
Time Frame: From date of randomization to follow-up visit Month 36 or death due to any cause, whichever came first, assessed up to 60 months
|
Safety and Tolerability assessed according to the NCI-CTC AE version 5
|
From date of randomization to follow-up visit Month 36 or death due to any cause, whichever came first, assessed up to 60 months
|
Quality of Life using European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30)
Time Frame: Every 6 months until the 36th month for each patient
|
Quality of Life using EORTC QLQ-C30 questionnaire.
64 questions related to cancer impact on health and daily activities composed this questionnaire.
Each item has to be graded from 1 to 4 ( 1 = not at all; 4 = very much).
More the score is high, worst the quality of life is.
|
Every 6 months until the 36th month for each patient
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Isabelle RAY-COQUARD, MD PhD, Centre Leon Berard
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Diseases
- Neoplasms, Complex and Mixed
- Neoplasms, Connective Tissue
- Endometrial Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Sarcoma
- Sarcoma, Endometrial Stromal
- Endometrial Stromal Tumors
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormone Antagonists
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Letrozole
- Exemestane
- Aromatase Inhibitors
Other Study ID Numbers
- ET17-200 BRF-ESS
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Low Grade Endometrial Stromal Sarcoma
-
Lei LiRecruitingRecurrence | Survival Outcomes | Adjuvant Therapy | Hormone Therapy | Low Grade Endometrial Stromal Sarcoma of Uterus (Diagnosis) | Fertility-sparing Surgery | Fertility OutcomesChina
-
Memorial Sloan Kettering Cancer CenterBristol-Myers SquibbCompletedCarcinosarcoma | Leiomyosarcoma | Endometrial Carcinoma | Uterine Cancer | Clear Cell Carcinoma | Undifferentiated Sarcoma | High Grade Endometrial Stromal SarcomaUnited States
-
Frederic AmantKom Op Tegen Kanker; FWO Research Fund FlandersRecruitingEndometrial Cancer | Endometrial Stromal Sarcoma | Sex Cord Stromal Tumor | Adenosarcoma of Uterus | Leiomyosarcoma Uterus | Serous Ovarian TumorBelgium
-
Assaf-Harofeh Medical CenterUnknownSoft Tissue Sarcoma | Osteosarcoma | Chondrosarcoma | Bone Sarcoma | Desmoplastic Small Round Cell Tumor | Gastrointestinal Stromal Sarcoma | Ewing's Tumor Metastatic | Ewing's Tumor Recurrent
-
Novartis PharmaceuticalsCompletedAdrenocortical Adenoma | Endometrial Stromal SarcomasGermany, United States, Korea, Republic of, Hungary, Italy, Slovakia
-
National Cancer Institute (NCI)CompletedUterine Carcinosarcoma | Endometrial Stromal Sarcoma | Recurrent Adult Soft Tissue Sarcoma | Recurrent Uterine Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage III Uterine Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Stage IV Uterine Sarcoma | Dermatofibrosarcoma Protuberans | Adult Rhabdomyosarcoma and other conditionsCanada, United States
-
National Cancer Institute (NCI)RecruitingGastric Cancer | Gastric Neoplasm | Gastrointestinal Stromal Tumor (GIST) | Gastrointestinal Stromal Sarcoma | Gastrointestinal Stromal NeoplasmUnited States
-
M.D. Anderson Cancer CenterCompleted
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma | Endometrial Adenosquamous Carcinoma | Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation | Endometrioid Stromal SarcomaUnited States
-
HRYZ Biotech Co.Not yet recruitingLeiomyosarcoma | Fibrosarcoma | Liposarcoma | Angiosarcoma | Synovial Sarcoma | Endometrial Stromal Sarcoma | Undifferentiated Pleomorphic Sarcoma | Epithelioid Sarcoma | Desmoplastic Small Round Cell Tumor | Malignant Peripheral Nerve Sheath Tumors | Pleomorphic RhabdomyosarcomaChina
Clinical Trials on Aromatase Inhibitors
-
PfizerCompletedMetastatic Breast CancerSpain, Belgium, Sweden, United Kingdom, Austria, Germany, Switzerland
-
PfizerCompleted
-
PfizerCompletedMetastatic Breast CancerUnited States
-
Dartmouth-Hitchcock Medical CenterActive, not recruiting
-
Second Affiliated Hospital, School of Medicine,...GeneCast Biotechnology Co., Ltd.RecruitingLuminal B/HER2-negative Breast CancerChina
-
King Faisal Specialist Hospital & Research CenterUnknownAdvanced Breast CancerSaudi Arabia
-
University of MichiganRecruitingArthralgia | Aging | Breast Neoplasm FemaleUnited States
-
University of Wisconsin, MadisonCompletedBreast Cancer | Osteoporosis | Osteopenia | Fracture
-
Monica MitaCedars-Sinai Medical CenterTerminated
-
UNICANCERAgendiaRecruiting